A First-in-Human, Randomized, Placebo-controlled, Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including Receptor Occupancy Measurements After Single Dose of SDI-118 and an Assessment of Food Effect
Latest Information Update: 09 Aug 2022
At a glance
- Drugs ABBV 552 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; First in man
- Sponsors AbbVie
Most Recent Events
- 09 Aug 2022 New trial record